Press "Enter" to skip to content

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer’s blockbuster Ibrance.

Original source:

Also Read:   Most Americans would take coronavirus vaccine if deemed safe: Reuters/Ipsos poll